021-51111890
购物车（）
sales@molnova.cn
Cysteamine
CAS No. 60-23-1
Cysteamine ( β-MEA;β-Mercaptoethylamine;Decarboxycysteine;MEA;Thioethanolamine )
产品货号. M15246 CAS No. 60-23-1
An agent for the treatment of nephropathic cystinosis and an antioxidant.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 500MG | ￥405 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Cysteamine
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述An agent for the treatment of nephropathic cystinosis and an antioxidant.
-
产品描述An agent for the treatment of nephropathic cystinosis and an antioxidant; increases intracellular glutathione levels in cystinotic cells, also increases the rates of apoptosis in cystinotic cells; is an excellent scavenger of OH and HOCl and also reacts with H2O2; significantly increase the intracellular GSH levels; also causes autophagosome accumulation in cancer cells.Other Indication Approved
-
同义词β-MEA;β-Mercaptoethylamine;Decarboxycysteine;MEA;Thioethanolamine
-
通路Autophagy
-
靶点Autophagy
-
受体Cystine;NPYR2;SomatostatinReceptor
-
研究领域Other Indications
-
适应症Other Disease
化学信息
-
CAS Number60-23-1
-
分子量77.15
-
分子式C2H7NS
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESNCCS
-
化学全称Ethanethiol, 2-amino-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Besouw, M, et al. Drug Discov Today, 2013. 18(15-16): p. 785-92.
2. de Matos, D.G, et al. Mol Reprod Dev, 1995. 42(4): p. 432-6.
3. Wan XM, et al. Int J Cancer. 2011 Sep 1;129(5):1087-95.
2. de Matos, D.G, et al. Mol Reprod Dev, 1995. 42(4): p. 432-6.
3. Wan XM, et al. Int J Cancer. 2011 Sep 1;129(5):1087-95.
产品手册
关联产品
-
rel-(8R,8'R)-dimethy...
rel-(8R,8'R)-Dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan is a chemical constituent of the fruit of Myristica fragrans.
-
Sulfanilamide
Sulfanilamide is a competitive inhibitor for bacterial enzymedihydropteroate synthetasewithIC50of 320 μM.
-
LYN-1604 2HCl 221675...
LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.LYN-1604, to be the best candidate for a ULK1 agonist.LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo.
